DOCSLIB.ORG

Multi-Discipline Review/Summary, Clinical, Non-Clinical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multi-Discipline Review/Summary, Clinical, Non-Clinical CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209115Orig1s000 MULTI-DISCIPLINE REVIEW Summary / Clinical / Non-Clinical NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) 1 NDA/BLA Multi-disciplinary Review and Evaluation Application Type NDA Application Number(s) 209115 Priority or Standard Priority Submit Date(s) June 23, 2016 Received Date(s) June 23, 2016 PDUFA Goal Date February 23, 2017 Division/Office DOP1/OHOP Review Completion Date November 22, 2016 Established Name Rucaparib (Proposed) Trade Name RUBRACA Pharmacologic Class Poly (ADP-Ribose) Polymerase 1 inhibitor Code name AG-014669, PF-01367338, Applicant Clovis Oncology, Inc. Formulation(s) Oral tablet Dosing Regimen 600 mg PO BID Applicant Proposed Rubraca is indicated as monotherapy treatment of advanced ovarian Indication(s)/Population(s) cancer in patients with deleterious BRCA-mutated tumors, inclusive of both germline BRCA and somatic BRCA mutations (as detected by an FDA approved test), and who have been treated with two or more chemotherapies. Recommendation on Accelerated approval Regulatory Action Recommended Rubraca™ is indicated as monotherapy for the treatment of patients Indication(s)/Population(s) with deleterious BRCA mutation (germline and/or somatic) associated (if applicable) advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca. 1-1 Version date: February 1, 2016 for initial rollout (NME/original BLA reviews) Reference ID: 40178304028244 NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) Contents 1 NDA/BLA Multi-disciplinary Review and Evaluation .......................................................................... 1-1 Reviewers of Multi-Disciplinary Review and Evaluation ............................................................................ 1-4 Additional Reviewers of Application .......................................................................................................... 1-4 Glossary ...................................................................................................................................................... 1-5 1 Executive Summary ............................................................................................................................ 1-7 1.1. Product Introduction .................................................................................................................. 1-7 1.2. Conclusions on the Substantial Evidence of Effectiveness ........................................................ 1-7 1.3. Benefit-Risk Assessment ............................................................................................................ 1-9 2 Therapeutic Context .......................................................................................................................... 2-1 2.1. Analysis of Condition.................................................................................................................. 2-1 2.2. Analysis of Current Treatment Options ..................................................................................... 2-2 3 Regulatory Background ...................................................................................................................... 3-1 3.1. U.S. Regulatory Actions and Marketing History ......................................................................... 3-1 3.2. Summary of Presubmission/Submission Regulatory Activity .................................................... 3-1 4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................................................. 4-1 4.1. Office of Scientific Investigations (OSI) ...................................................................................... 4-1 4.2. Product Quality .......................................................................................................................... 4-1 4.3. Clinical Microbiology .................................................................................................................. 4-1 4.4. Devices and Companion Diagnostic Issues ................................................................................ 4-1 5 Advisory Committee Meeting and Other External Consultations ..................................................... 5-1 6 Pediatrics ............................................................................................................................................ 6-1 7 Risk Evaluation and Mitigation Strategies (REMS) ............................................................................. 7-1 7.1. Safety Issue(s) that Warrant Consideration of a REMS ............................................................. 7-1 7.2. Conditions of Use to Address Safety Issue(s) ............................................................................. 7-1 7.3. Recommendations on REMS ...................................................................................................... 7-1 8 Postmarketing Requirements and Commitments ............................................................................. 8-1 1-2 Version date: February 1, 2016 for initial rollout (NME/original BLA reviews) Reference ID: 40178304028244 9 Nonclinical Pharmacology/Toxicology 9‐1 9.1. Executive Summary 9‐2 9.2. Referenced NDAs, BLAs, DMFs 9‐4 9.3. Pharmacology 9‐4 9.4. ADME/PK 9‐8 9.5. Toxicology 9‐11 9.5.1. General Toxicology 9‐11 9.5.2. Genetic Toxicology 9‐17 9.5.3. Carcinogenicity 9‐20 9.5.4. Reproductive and Developmental Toxicology 9‐20 10. Clinical Pharmacology 10.1‐1 10.1. Executive Summary 10.1‐2 10.1.1. Recommendations 10.1‐3 10.1.2. Post‐Marketing Requirement (PMR) and Commitment (PMC) 10.1‐5 10.2. Summary of Clinical Pharmacology Assessment 10.2‐5 10.2.1. Pharmacology and Clinical Pharmacokinetics 10.2‐5 10.2.2. General Dosing and Therapeutic Individualization 10.2‐5 10.3. Comprehensive Clinical Pharmacology Review 10.3‐7 10.3.1. General Pharmacology and Pharmacokinetic Characteristics 10.3‐7 10.3.2. Clinical Pharmacology Questions 10.3‐9 10.4. OCP Appendices 10.4‐13 10.4.1. Bioanalysis Report 10.4‐13 10.4.2. General Clinical Pharmacology 10.4‐16 10.4.3. Pharmacometrics Population PK Analysis 10.4‐33 10.4.4. Pharmacometrics Exposure‐Response Analysis 10.4‐42 Reference ID: 4028244 10.4.5. Genomics Factors 10.4‐56 11 Statistical and Clinical and Evaluation 11‐1 11.1. Sources of Clinical Data and Review Strategy 11‐6 11.1.1. Table of Clinical Studies 11‐6 11.2.3. Review Strategy 11‐9 11.3. Review of Relevant Individual Trials Used to Support Efficacy 11‐10 11.1.1. Study CO‐338‐017, “ARIEL2” 11‐10 11.1.2. Study Results for Study CO‐338‐017, ARIEL2 11‐25 11.2.3. Study CO‐338‐010, “Study 10” 11‐27 11.1.4. Study Results for Study 10 11‐43 11.2.5. Study CO‐338‐023, RUCAPANC 11‐45 11.3 Integrated Review of Effectiveness 11‐47 11.3.1. Assessment of Efficacy Across Trials 11‐47 11.3.2. Integrated Assessment of Effectiveness 11‐62 11.4. Review of Safety 11‐63 11.4.1 Safety Review Approach 11‐63 11.4.2. Review of the Safety Database 11‐64 11.4.3. Adequacy of Applicant’s Clinical Safety Assessments 11‐66 11.4.4. Safety Results 11‐68 11.4.5. Analysis of Submission‐Specific Safety Issues 11‐91 11.4.6. Safety Analyses by Demographic Subgroups 11‐97 11.4.7. Specific Safety Studies/Clinical Trials 11‐99 11.4.8. Additional Safety Explorations 11‐99 11.4.9. Safety in the Postmarket Setting 11‐99 11.4.10. Integrated Assessment of Safety 11‐99 Reference ID: 4028244 SUMMARY AND CONCLUSIONS 11‐101 11.5. Statistical Issues 11‐101 11.6. Conclusions and Recommendations 11‐101 12 Appendices 12‐1 12.1. Financial Disclosure 12‐2 Reference ID: 4028244 NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) Table of Tables Table 1: Agents for the Treatment of Women with Advanced Ovarian Cancer ........................................ 2-3 1-3 Version date: February 1, 2016 for initial rollout (NME/original BLA reviews) Reference ID: 40178304028244 NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) Reviewers of Multi-Disciplinary Review and Evaluation Regulatory Project Manager Kim Robertson Nonclinical Reviewer Haw-Jyh (Brian) Chiu Nonclinical Team Leader Todd Palmby Office of Clinical Pharmacology Reviewer(s) Sarah Schrieber / Jinzhong Liu Office of Clinical Pharmacology Team Leader(s) Pengfei Song Associate Director for Labeling William Pierce Clinical Reviewer for Efficacy Sanjeeve Balasubramaniam Clinical Reviewer for Safety Sara Horton Clinical Team Leader Julia Beaver Statistical Reviewer Laura Fernandes Statistical Team Leader Shenghui Tang Cross-Disciplinary Team Leader Julia Beaver Division Director (DHOT) John Leighton Division Director (OCP) Nam Atiqur Rahman Division Director (OB) Rajeshwari Sridhara Division Director (OHOP) Geoffrey Kim Office Director (or designated signatory authority) Richard Pazdur Additional Reviewers of Application OPQ Kristine Leahy Microbiology Xing Wang OPDP Nicholas Senior OSI Lauren Iacono-Connor OSE/DEPI Carolyn McCloskey / Steven Bird OSE/DMEPA Tingting Gao OSE/DRISK Mei-Yean Chen Other OPQ=Office of Pharmaceutical Quality OPDP=Office of Prescription Drug Promotion OSI=Office of Scientific Investigations OSE= Office of Surveillance and Epidemiology DEPI= Division of Epidemiology DMEPA=Division
Load more

Recommended publications
  • Study Protocol
    Clovis Oncology, Inc. Clinical Protocol Oral rucaparib (CO-338) CO-338-014 7 July 2016 CONFIDENTIAL A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Protocol Number: CO-338-014 Investigational Product: Rucaparib (CO-338) Eudra CT Number: IND Number: Development Phase: Phase 3 Indications Studied: Platinum-sensitive, high-grade serous and endometrioid epithelial ovarian, primary peritoneal, and fallopian tube cancer Sponsor Name and Address: Clovis Oncology, Inc. 5500 Flatiron Parkway Suite 100 Boulder, CO 80301 USA Phone Number: 303-625-5000 Facsimile Number: 303-245-0360 Responsible Medical Officer: Compliance Statement: This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, clinical research guidelines established by the Code of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), and ICH GCP Guidelines. Essential study documents will be archived in accordance with applicable regulations. CONFIDENTIALITY STATEMENT The information in this document contains commercial information and trade secrets that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable laws and regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you which is indicated as privileged or confidential. 1 Clovis Oncology, Inc. Clinical Protocol Oral rucaparib (CO-338) CO-338-014 Coordinating Investigators for the Study Coordinating Investigator for North America: Coordinating Investigator for Europe, Middle East, and Asia Pacific: 2 Clovis Oncology, Inc.
    [Show full text]
  • Withdrawal Assessment Report - Orphan Maintenance
    17 January 2019 EMA/22653/2019 Committee for Orphan Medicinal Products Withdrawal Assessment Report - Orphan Maintenance Rubraca (rucaparib) Treatment of ovarian cancer EU/3/12/1049 (EMA/OD/085/12) Sponsor: Clovis Oncology UK Limited Note Assessment report as adopted by the COMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged Table of contents 1. Product and administrative information .................................................. 3 2. Grounds for the COMP opinion at the designation stage .......................... 5 3. Review of criteria for orphan designation at the time of type II variation .................................................................................................................... 5 Article 3(1)(a) of Regulation (EC) No 141/2000 .............................................................. 5 Article 3(1)(b) of Regulation (EC) No 141/2000 .............................................................. 6 4. COMP list of issues .................................................................................. 8 Withdrawal Assessment Report - Orphan Maintenance EMA/22653/2019 Page 2/8 1. Product and administrative information Product Active substance Rucaparib International Non-Proprietary
    [Show full text]
  • ARIEL4: an International, Randomised Phase 3 Study Of
    ARIEL4: An International, Randomised Phase 3 Study of Rucaparib vs Chemotherapy in BRCA1- or BRCA2-Mutated, Abstract ESGO7-0665 Relapsed Ovarian Cancer (OC) Rebecca S. Kristeleit,1 Domenica Lorusso,2 Ana Oaknin,3 Tamar Safra,4 Elizabeth M. Swisher,5 Igor M. Bondarenko,6 Tomasz Huzarski,7 Jaroslav Klat,8 Vladimir Moiseyenko,9 Róbert Póka,10 Luciana S. Viola,11 Chris Tankersley,12 Lara Maloney,12 Sandra Goble,12 Caro Unger,12 Adam Dowson,12 Heidi Giordano,12 Amit M. Oza13 1University College London Cancer Institute, London, UK; 2MITO and Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 4Sackler School of Medicine, Tel Aviv University and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 5University of Washington, Seattle, WA, USA; 6Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital, Dnipropetrovsk, Ukraine; 7Private Health Care Innovative Medicine, Grzepnica, Poland; 8University Hospital Ostrava, Ostrava, Czech Republic; 9NN. Petrov Research Institute of Oncology Cancer Center, St. Petersburg, Russian Federation; 10Debrecen University Clinical Center, Debrecen, Hungary; 11Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; 12Clovis Oncology, Inc., Boulder, CO, USA; 13Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada INTRODUCTION • In high-grade OC, including fallopian tube and primary peritoneal cancer, ≈18% and ≈7% of
    [Show full text]
  • Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma: The
    Original research Rucaparib maintenance treatment for Int J Gynecol Cancer: first published as 10.1136/ijgc-2020-002240 on 8 June 2021. Downloaded from INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Original research Editorials Joint statement Society statement recurrent ovarian carcinoma: the effects of Meeting summary Review articles Consensus statement Clinical trial Case study Video articles Educational video lecture progression- free interval and prior therapies Images Pathology archives Corners of the world Commentary Letters ijgc.bmj.com on efficacy and safety in the randomized phase III trial ARIEL3 Andrew R Clamp,1 Domenica Lorusso ,2 Amit M Oza,3 Carol Aghajanian,4 Ana Oaknin,5 Andrew Dean,6 Nicoletta Colombo,7 Johanne I Weberpals,8 Giovanni Scambia,9 Alexandra Leary,10 Robert W Holloway,11 Margarita Amenedo Gancedo,12 Peter C Fong,13 Jeffrey C Goh,14,15 David M O’Malley,16 Deborah K Armstrong,17 Susana Banerjee,18 Jesus García- Donas,19 Elizabeth M Swisher,20 Terri Cameron,21 Sandra Goble,22 Robert L Coleman,23 Jonathan A Ledermann 24 ► Additional supplemental HIGHLIGHTS material is published online • Rucaparib extended progression- free survival versus placebo regardless of penultimate progression- free interval. only. To view, please visit the • Rucaparib extended progression- free survival versus placebo regardless of prior chemotherapies or bevacizumab use. journal online (http:// dx. doi. org/ • The safety profile of rucaparib was consistent across all subgroups. 10. 1136/ ijgc- 2020- 002240). For numbered affiliations see ABSTRACT subgroups, median progression- free survival was also end of article. Introduction In ARIEL3 (NCT01968213), the significantly longer with rucaparib versus placebo in the poly(adenosine diphosphate-ribose) polymerase inhibitor BRCA-mutant and homologous recombination deficient Correspondence to rucaparib significantly improved progression-free survival cohorts.
    [Show full text]
  • Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
    G C A T T A C G G C A T genes Review Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation Reka Varnai 1,2, Leena M. Koskinen 3, Laura E. Mäntylä 3, Istvan Szabo 4,5, Liesel M. FitzGerald 6 and Csilla Sipeky 3,* 1 Department of Primary Health Care, University of Pécs, Rákóczi u 2, H-7623 Pécs, Hungary 2 Faculty of Health Sciences, Doctoral School of Health Sciences, University of Pécs, Vörösmarty u 4, H-7621 Pécs, Hungary 3 Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland 4 Institute of Sport Sciences and Physical Education, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 5 Faculty of Sciences, Doctoral School of Biology and Sportbiology, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia * Correspondence: csilla.sipeky@utu.fi Received: 17 June 2019; Accepted: 5 August 2019; Published: 8 August 2019 Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
    [Show full text]
  • Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
    pharmaceuticals Review Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma Rita Rebelo 1,2,† ,Bárbara Polónia 1,2,†,Lúcio Lara Santos 3,4, M. Helena Vasconcelos 1,2,5,* and Cristina P. R. Xavier 1,2,5,* 1 Cancer Drug Resistance Group, IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal; [email protected] (R.R.); [email protected] (B.P.) 2 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal 3 Experimental Pathology and Therapeutics Group, IPO—Instituto Português de Oncologia, 4200-072 Porto, Portugal; [email protected] 4 ICBAS—Biomedical Sciences Institute Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal 5 Department of Biological Sciences, FFUP—Faculty of Pharmacy of the University of Porto, 4200-135 Porto, Portugal * Correspondence: [email protected] (M.H.V.); [email protected] (C.P.R.X.) † These authors equally contributed to this work. Abstract: Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication.
    [Show full text]
  • Clinical Policy: Rucaparib (Rubraca)
    Clinical Policy: Rucaparib (Rubraca) Reference Number: CP.PHAR.350 Effective Date: 09.01.17 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Rucaparib (Rubraca®) is a poly (ADP-ribose) polymerase (PARP) inhibitor. FDA Approved Indication(s) Rubraca is indicated: For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA- approved companion diagnostic for Rubraca For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum- based chemotherapy Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Rubraca is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Ovarian Cancer (must meet all): 1. Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. One of the following (a or b): a. Both i and ii: i. Deleterious or suspected deleterious germline and/or somatic BRCA mutation; ii. Failure of ≥ 2 lines of chemotherapy, unless contraindicated or clinically significant adverse effects are experienced; b. Completed ≥ 2 platinum-based chemotherapy regimens and is in a complete or partial response; 5.
    [Show full text]
  • Polyclonal BRCA2 Mutations Following Carboplatin Treatment Confer Resistance to the PARP Inhibitor Rucaparib in a Patient with Mcrpc: a Case Report Andrew D
    Simmons et al. BMC Cancer (2020) 20:215 https://doi.org/10.1186/s12885-020-6657-2 CASE REPORT Open Access Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report Andrew D. Simmons1, Minh Nguyen1 and Elias Pintus2,3* Abstract Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutant ovarian and breast cancers, and are now being evaluated in metastatic castration-resistant prostate cancer (mCRPC). Reversion mutations that restore BRCA1/2 function have been shown to be responsible for resistance to platinum-based chemotherapy and PARP inhibitors, however there is no information on the sequential use of these agents in prostate cancer. Case presentation: A patient with mCRPC associated with a germline BRCA2 mutation was sequentially treated with carboplatin and the PARP inhibitor rucaparib. Genomic profiling of the available baseline tumor and progression blood samples using next-generation sequencing panel tests identified polyclonal BRCA2 reversion mutations post carboplatin treatment but prior to rucaparib treatment. A total of 12 somatic reversion mutations were detected and ranged from small indels to larger deletions of up to 387 amino acids. These alterations are all predicted to restore the BRCA2 open reading frame and potentially protein function. The patient received limited benefit while on rucaparib, likely due to these reversion mutations observed prior to treatment. Conclusions: Here we report a case of a patient with prostate cancer who received a platinum agent and PARP inhibitor sequentially and in whom polyclonal BRCA2 reversion mutations were identified as the likely mechanism of acquired resistance to carboplatin and primary resistance to PARP inhibition.
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Study Protocol
    Clovis Oncology, Inc. Clinical Protocol Oral rucaparib (CO-338) CO-338-010 29 June 2016 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Ovarian Cancer or Other Solid Tumor Protocol Number: CO-338-010 Investigational Product: Oral rucaparib (CO-338) Eudra CT Number: IND Number: Development Phase: Phase I/II Indication Studied: Locally advanced or metastatic solid tumors, including lymphoma, and germline BRCA (gBRCA) ovarian cancer Sponsor Name and Address: Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 U.S.A. Responsible Medical Officer: Compliance Statement: This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, clinical research guidelines established by the Code of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), and International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. Essential study documents will be archived in accordance with applicable regulations. CONFIDENTIALITY STATEMENT The information in this document contains commercial information and trade secrets that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable laws and regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all
    [Show full text]
  • Standard Oncology Criteria C16154-A
    Prior Authorization Criteria Standard Oncology Criteria Policy Number: C16154-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DATE DUE BEFORE 03/2016 12/2/2020 1/26/2022 HCPCS CODING TYPE OF CRITERIA LAST P&T APPROVAL/VERSION N/A RxPA Q1 2021 20210127C16154-A PRODUCTS AFFECTED: See dosage forms DRUG CLASS: Antineoplastic ROUTE OF ADMINISTRATION: Variable per drug PLACE OF SERVICE: Retail Pharmacy, Specialty Pharmacy, Buy and Bill- please refer to specialty pharmacy list by drug AVAILABLE DOSAGE FORMS: Abraxane (paclitaxel protein-bound) Cabometyx (cabozantinib) Erwinaze (asparaginase) Actimmune (interferon gamma-1b) Calquence (acalbrutinib) Erwinia (chrysantemi) Adriamycin (doxorubicin) Campath (alemtuzumab) Ethyol (amifostine) Adrucil (fluorouracil) Camptosar (irinotecan) Etopophos (etoposide phosphate) Afinitor (everolimus) Caprelsa (vandetanib) Evomela (melphalan) Alecensa (alectinib) Casodex (bicalutamide) Fareston (toremifene) Alimta (pemetrexed disodium) Cerubidine (danorubicin) Farydak (panbinostat) Aliqopa (copanlisib) Clolar (clofarabine) Faslodex (fulvestrant) Alkeran (melphalan) Cometriq (cabozantinib) Femara (letrozole) Alunbrig (brigatinib) Copiktra (duvelisib) Firmagon (degarelix) Arimidex (anastrozole) Cosmegen (dactinomycin) Floxuridine Aromasin (exemestane) Cotellic (cobimetinib) Fludara (fludarbine) Arranon (nelarabine) Cyramza (ramucirumab) Folotyn (pralatrexate) Arzerra (ofatumumab) Cytosar-U (cytarabine) Fusilev (levoleucovorin) Asparlas (calaspargase pegol-mknl Cytoxan (cyclophosphamide)
    [Show full text]
  • Clovis Oncology Highlights Rubraca® (Rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
    NEWS RELEASE Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021 4/10/2021 Findings from the Phase 1b RAMP study evaluating the combination of Rubraca and Xtandi® (enzalutamide) in men with unselected mCRPC lay the groundwork for the Phase 3 CASPAR study which is expected to begin enrolling patients shortly Phase 1 data from the RUCA-J study of Rubraca in Japanese patients with advanced solid tumors show similar safety and pharmacokinetic proles to those observed in Western patients BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021. “We remain committed to understanding how Rubraca may benet patients with cancer, and the data presented at AACR further enhance our understanding in dierent patient populations and solid tumor types,” said Patrick J. Mahay, President and CEO of Clovis Oncology. “The Phase 1b RAMP data for the combination of Rubraca and Xtandi in unselected mCRPC patients help inform the Alliance for Clinical Oncology-sponsored CASPAR Phase 3 trial which is expected to begin enrolling patients soon, and we look forward to learning more about the combination.” Following are details of the Clovis-sponsored presentations at AACR 2021: Poster Presentation 445: Genomic Characteristics and Response to Rucaparib and Enzalutamide in the Phase 1b RAMP Study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients 1 Lead author: Arpit Rao, MBBS, University of Minnesota, Minneapolis, USA Session: Clinical Research Date/Time: April 10, 2021, 8:30 a.m.
    [Show full text]